Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
Cristiana Sessa(Université Claude Bernard Lyon 1), Nicoletta Colombo(University of Milan), Cristina Noberasco(European Institute of Oncology), Maurizio D’Incalci(Humanitas University), Luca Gianni(IRCCS Ospedale San Raffaele), E. Dall’O’(European Institute of Oncology), Flavia Zanaboni, Silvia Marsoni(Candiolo Cancer Institute), Jean Bauer(European Institute of Oncology), Antonella Perotti(European Institute of Oncology), Giuseppe Curigliano(European Institute of Oncology), José Jimeno(European Organisation for Research and Treatment of Cancer), Filippo de Braud(University of Milan)
Cited by 164
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k